A prospective study to allow uniform treatment and collection of information on biomarkers such as TMB, PD-L1, MSI/MMR, tumor-infiltrating lymphocytes, whole-exome sequencing analysis on tumor samples and intestinal microbiome composition may be helpful to identify the resistance mechanisms. This evidence concerns the gene CD274 and neoplasm.